Holen Sie sich die Stockscreener-App
6.89
0.15%
-0.03
Schlusskurs vom Vortag:
$6.86
Offen:
$6.77
24-Stunden-Volumen:
37,220
Relative Volume:
0.17
Marktkapitalisierung:
$359.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.93M
KGV:
-9.6055
EPS:
-0.7173
Netto-Cashflow:
$-27.71M
1W Leistung:
-2.42%
1M Leistung:
-16.77%
6M Leistung:
-1.30%
1J Leistung:
+67.89%
1-Tages-Spanne:
$6.77
$7.01
1-Wochen-Bereich:
$6.67
$7.41
52-Wochen-Spanne:
$3.19
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.905 | 357.25M | 0 | -31.93M | -27.71M | -0.7173 |
VRTX
Vertex Pharmaceuticals Inc
|
455.52 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.92 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.19 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.44 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.46 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-30 | Eingeleitet | TD Cowen | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday - MarketBeat
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - weeklyvoice.com
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
Market Review: How does DiaMedica Therapeutics Inc compare to its peers2026 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Cooperman Leon G Raises Position in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? - MSN
DiaMedica receives Health Canada clearance for preeclampsia study - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC) - The Globe and Mail
What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now? - MSN
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday - MarketBeat
Geopolitics Watch: Is DiaMedica Therapeutics Inc. stock attractive for ETFsQuarterly Profit Review & Daily Profit Focused Screening - Naître et grandir
DiaMedica Therapeutics raises capital via share offering - MSN
DiaMedica Therapeutics, Inc. $DMAC Shares Purchased by Paragon Associates & Paragon Associates II Joint Venture - MarketBeat
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Diamedica Therapeutics (DMAC) and Veeva Systems (VEEV) - The Globe and Mail
DiaMedica receives Health Canada clearance for preeclampsia study By Investing.com - Investing.com South Africa
Sentiment Watch: Whats the fair value of AEV CL stockAnalyst Downgrade & Low Risk Investment Opportunities - baoquankhu1.vn
DiaMedica (DMAC) Gains Health Canada Approval for Preeclampsia T - GuruFocus
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - The AI Journal
DiaMedica Therapeutics receives Health Canada clearance to initiate phase 2 study of DM199 in preeclampsia - marketscreener.com
Corient IA LLC Acquires New Holdings in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
DMAC SEC FilingsDiamedica Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Risk Analysis: Can DiaMedica Therapeutics Inc lead its sector in growthPortfolio Value Summary & Fast Momentum Entry Tips - baoquankhu1.vn
DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.1%Time to Sell? - MarketBeat
Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight - Yahoo Finance
Rate Cut: Is DiaMedica Therapeutics Inc stock a top performer YTDJuly 2025 Price Swings & Daily Market Momentum Tracking - baoquankhu1.vn
Earnings Recap: Can DiaMedica Therapeutics Inc keep up with sector leadersGold Moves & Consistent Profit Trading Strategies - baoquankhu1.vn
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire
DMAC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sentiment Recap: How does DiaMedica Therapeutics Inc compare to its peersJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
How DiaMedica Therapeutics Inc. stock trades before earningsJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - mfd.ru
Fichthorn reports 0.3% DiaMedica (DMAC) stake as Dialectic entities exit - Stock Titan
Trading Recap: Is FURY a play on infrastructure spendingWeekly Market Outlook & Community Trade Idea Sharing - baoquankhu1.vn
DiaMedica Therapeutics Insiders Added US$58.4m Of Stock To Their Holdings - Yahoo Finance
Is DiaMedica Therapeutics Inc a cyclical or defensive stockAnalyst Downgrade & Technical Confirmation Trade Alerts - baoquankhu1.vn
DMAC Technical Analysis & Stock Price Forecast - Intellectia AI
Swing Trade: Can DiaMedica Therapeutics Inc keep up with sector leadersTrade Signal Summary & Community Supported Trade Ideas - baoquankhu1.vn
Is DiaMedica Therapeutics Inc. stock a top performer YTDJuly 2025 Volume & AI Enhanced Trading Alerts - mfd.ru
Highs Report: How does DiaMedica Therapeutics Inc compare to its peersChart Signals & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics Strengthens Balance Sheet With $12.2 Million Capital Raise While Advancing Preeclampsia Program - Longbridge
Dividend Watch: Can DiaMedica Therapeutics Inc. keep up with sector leaders2025 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Insiders continue to buy DiaMedica Therapeutics Inc. (NASDAQ:DMAC) and now own 47% shares - simplywall.st
Cantor Fitzgerald Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on DiaMedica stock - Investing.com
Aug Final Week: Whats next for CWAN stockJuly 2025 Update & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
What technical charts say about DiaMedica Therapeutics Inc. stock2025 Volume Leaders & Free Expert Approved Momentum Trade Ideas - bollywoodhelpline.com
Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Declines By 22.8% - MarketBeat
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Diamedica Therapeutics Inc-Aktie (DMAC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Nov 21 '25 |
Buy |
7.41 |
208,872 |
1,547,574 |
8,712,390 |
| STAHLBERG JAN | 10% Owner |
Nov 18 '25 |
Buy |
6.75 |
182,882 |
1,234,618 |
8,134,740 |
| STAHLBERG JAN | 10% Owner |
Nov 17 '25 |
Buy |
6.52 |
187,393 |
1,221,165 |
7,951,858 |
| STAHLBERG JAN | 10% Owner |
Nov 20 '25 |
Buy |
7.41 |
128,426 |
951,213 |
8,503,518 |
| STAHLBERG JAN | 10% Owner |
Nov 25 '25 |
Buy |
8.57 |
73,099 |
626,817 |
8,825,742 |
| STAHLBERG JAN | 10% Owner |
Nov 24 '25 |
Buy |
7.89 |
40,253 |
317,721 |
8,752,643 |
| Parsons James T. | Director |
Nov 21 '25 |
Option Exercise |
2.20 |
12,000 |
26,400 |
87,854 |
| STAHLBERG JAN | 10% Owner |
Aug 25 '25 |
Buy |
6.00 |
338,265 |
2,029,252 |
7,654,045 |
| STAHLBERG JAN | 10% Owner |
Aug 13 '25 |
Buy |
5.91 |
293,601 |
1,734,918 |
7,058,066 |
| STAHLBERG JAN | 10% Owner |
Aug 14 '25 |
Buy |
5.99 |
70,414 |
421,921 |
7,128,480 |
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):